ALGN ALIGN TECHNOLOGY INC
Price Chart
Executive Summary
The Delaware district court denied Align's motion to dismiss Densys's patent infringement claims on § 101 subject-matter eligibility grounds, ruling that both asserted patents (the '707 and '257 patents) are directed to patent-eligible technological improvements in intra-oral 3D imaging rather than abstract ideas. However, the court granted Align's motion to dismiss for failure to state a claim on direct infringement of the '257 patent (lack of plausible 'memory' element) and dismissed all willful and indirect infringement claims against Align without prejudice for insufficient pleading of knowledge. The case survives on direct infringement of the '707 patent, preserving material litigation exposure for Align's iTero scanner product line.
Court Ruling Details
Actionable Insight
The denial of Align's § 101 challenge means the case survives into discovery and claim construction, creating ongoing litigation overhang for ALGN's iTero scanner revenue stream. However, the dismissal of willful/indirect claims limits damages exposure to post-complaint conduct only. Monitor for claim construction rulings (especially on 'random patterns' and 'memory' terms) and any settlement developments — these are the next key catalysts. The stock has underperformed historically on neutral calls (avg T+20 -11.2%), suggesting the market may already discount some litigation risk, but a surviving patent case on a core product is a fresh negative signal.
Key Facts
- Court denied Align's motion to dismiss on § 101 patent-eligibility for both the '707 and '257 patents — patents survive as valid.
- Court granted Align's motion to dismiss direct infringement claim for the '257 patent (no plausible 'memory' element), but without prejudice.
- All willful and indirect infringement claims against Align dismissed without prejudice for insufficient pleading of knowledge.
- Direct infringement claim on the '707 patent survives — Align's iTero scanners remain accused of infringing a key intra-oral scanning patent.
- The ruling is interlocutory (motion to dismiss stage), not a final judgment — case proceeds to discovery and claim construction.
- Align's iTero scanner product line (iTero Element 5D, iTero Lumina, etc.) is the accused product category.
Financial Impact
No damages awarded or pleaded amount stated in the opinion. Potential exposure from a surviving patent infringement case on a core product line (iTero scanners) — material but unquantifiable at this stage.
Risk Factors
- If Densys prevails on the '707 patent, Align could face an injunction against iTero scanner sales or substantial ongoing royalties.
- Claim construction on key terms ('random patterns', 'memory') could expand or contract infringement exposure significantly.
- Parallel case against Medit (dismissed more broadly) may reduce co-defendant leverage but does not directly affect Align.
- Appeal of § 101 ruling is possible but unlikely to succeed given the court's thorough analysis aligning with Federal Circuit precedent (Thales Visionix, Koninklijke).
Market Snapshot
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-rrpst4hh-ALGN |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 29, 2026
12d ago
|
Court Ruling
| $174.75 $161.71 | ▲ +7.46% | ▲ +7.17% | $172.05 (+1.55%) |
|
Apr 17, 2026
7w ago
|
DEFA14A
| $191.43 $184.55 | ▼ −3.59% | ▼ −4.51% | $172.05 (−10.13%) |
|
Apr 7, 2026
9w ago
|
DEFA14A
| $176.69 $185.60 | ▲ +5.04% | ▲ +1.53% | $172.05 (−2.63%) |
|
Feb 28, 2026
14w ago
|
Institutional Cluster
| $188.84 $174.31 | ▼ −7.69% | ▼ −6.49% | $172.05 (−8.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access